CN104105496A - Hawthorn and kudzu and their effect on cardiovascular diseases - Google Patents
Hawthorn and kudzu and their effect on cardiovascular diseases Download PDFInfo
- Publication number
- CN104105496A CN104105496A CN201380008674.XA CN201380008674A CN104105496A CN 104105496 A CN104105496 A CN 104105496A CN 201380008674 A CN201380008674 A CN 201380008674A CN 104105496 A CN104105496 A CN 104105496A
- Authority
- CN
- China
- Prior art keywords
- compositions
- applying
- aforementioned
- fructus crataegi
- pueraria lobota
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention generally relates to the field of health and wellness. In particular, the present invention addresses hyperlipidemia, hypercholesterolemia and disorders associated therewith. For example, the present invention describes a composition comprising kudzu and hawthorn for use in the treatment, alleviation or prevention of disorders associated with hypercholesterolemia.
Description
The present invention relates to healthy and kilter field in general.Particularly, the present invention is devoted to hyperlipemia, hypercholesterolemia and relative obstacle.For example, the invention describes the compositions containing Pueraria lobota (kudzu) and Fructus Crataegi (hawthorn), the obstacle that it is used for the treatment of, alleviates or prevention is relevant to hypercholesterolemia.
Cardiovascular disease (CVDs) is dead and disabled first cause in the world.The people who is subject to every year CVDs bad attack is more than any other reason.According to WHO report, in 2008, estimate that 1,730 ten thousand people die from CVDs, account for 30% of global all death.In these death, estimate that 7,300,000 is due to coronary heart disease, 6,200,000 people are due to apoplexy.Before the year two thousand thirty, almost 2,360 ten thousand people will die from CVDs, mainly due to heart disease and apoplexy.These are inferred to be dead single first cause.
Known Pueraria lobota and Fructus Crataegi have effect to reducing blood fat, and they have all been listed in ten large the most frequently used China tradition compositions in treatment hyperlipemia.Yet these two kinds of compositions have their limitation.
Fructus Crataegi is that the rosaceous shrub/dungarunga that blooms has use history widely in cardiovascular disease, can trace back to for the 1st century.Fructus Crataegi has shown that reduction has effect likely to cholesterolemia.Yet for reaching remarkable effect biology, every daily consumption Fructus Crataegi juice often causes stomach discomfort, reason is due to its tart flavour.
In addition, Fructus Crataegi is limited to the reducing effect of blood triglyceride, and in blood fat, blood triglyceride is important risk factor for cardiovascular disease.
Pueraria lobota (Radix Pueraria) is the abundant source of isoflavone glucoside, is being used for the treatment of traditionally alcoholism, diabetes, gastroenteritis and deafness.In Pueraria lobota, the abundantest isoflavone is puerarin (daidzein 8-C-glucoside).Its compound also comprises daidzein, daidzin (daidzein 7-O-glucoside) and other osajins.Original observed to be that puerarin reduces apolipoprotein (ApoB100) secretion in hepatocyte, but in enteral cell line, do not have this effect (Lee etc., 2002 (Lee JS, etc., BMC Complement Altern Med.2002 December 16 days; 2:12.Epub?2002)。
When avoiding the low dosage of obvious less desirable side effect or intestinal discomfort to use, Fructus Crataegi or Pueraria lobota reduce not statistically effect significantly to blood fat or cholesterol.
Yet this area has no side effect for using safely and the natural medicine that can reduce the risk of suffering from cardiovascular disorder has clear and definite needs.
The inventor has been devoted to this demand.
Therefore, the object of the invention is to improve prior art level, the natural composition that overcomes prior art problem and be devoted to needs mentioned above is particularly provided.
The inventor surprisingly finds that the theme of independent claims realized object of the present invention.The theme of dependent claims has further developed central idea of the present invention.
Particularly, the inventor finds (when using together) Fructus Crataegi and Ge Fahui synergism in hamster model, and can statistically reduce significantly blood fat and blood LDL-C level, keep the dosage separately of Pueraria lobota and Fructus Crataegi enough low to avoid less desirable side effect and discomfort simultaneously.
Do not expect bound by theoryly, the inventor believes that this useful effect is increase Cholesterol Excretion simultaneously and reduce cholesterol absorption due to Fructus Crataegi and Pueraria lobota.
Therefore, a part of the present invention relates to the compositions that comprises Pueraria lobota and Fructus Crataegi, the obstacle that it is used for the treatment of, alleviates or prevention is relevant to hyperlipemia and/or hypercholesterolemia.
The invention still further relates to the application in preparation compositions of Pueraria lobota and Fructus Crataegi, the obstacle that described compositions is used for the treatment of, alleviates or prevention is relevant to hyperlipemia and/or hypercholesterolemia.
The obstacle relevant to hyperlipemia and/or hypercholesterolemia is well known to those skilled in the art that (referring to such as Bhatnagar D. etc., BMJ 2008; 337:a993, is introduced into as a reference).For example, hypercholesterolemia is the one of the main reasons of atherosclerosis or coronary heart disease.
Hyperlipemia is characterized as in blood any or all lipid and/or the level of the abnormal rising of lipoprotein.
For example, the obstacle relevant to hyperlipemia and/or hypercholesterolemia can be cardiovascular disorder.
Cardiovascular disorder is one group of obstacle of heart and blood vessel, comprises coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, venous thrombosis and pulmonary infarction etc." cardiovascular disorder " generally refers to any disease that affects cardiovascular system, refers to especially those obstacles relevant with atherosclerosis (arteriopathy).These diseases have similar reason, mechanism and treatment conventionally.
Atherosclerosis is the accumulation that is called the fat deposit thing (such as cholesterol) of the speckle on Wall of Artery.When cardiac problems being detected, atherosclerosis is conventionally quite serious, has developed many decades.Be more commonly that speckle breaks suddenly, cause the formation of thrombosis, it is rapid block blood flow, causes peripheral organization only dead in 5 minutes.This catastrophic event is called as infarction.One of situation about the most often confirming is called as coronary artery thrombosis coronarius, causes myocardial infarction (heart attack).Identical process in leading to the tremulous pulse of brain is commonly referred to apoplexy.Normal conditions in another very serious morbid state are the limpings that cause due to lower limb blood supply insufficiency, and the two causes jointly conventionally by narrow and grumeleuse, to cause narrow aneurysm section.
Even atherosclerotic main cause is unknown, it is impact arterial vascular syndrome---the inflammatory response in arterial wall, the latter is mainly caused by gathering of macrophage, and by low density lipoprotein, LDL (LDL, carry the plasma lipoprotein of cholesterol and triglyceride) promote, and by functional high density lipoprotein (HDL), from macrophage, suitably do not remove metabolism of lipid and cholesterol.It is commonly called sclerosis or the raw dirt (furring) of tremulous pulse.This is to be caused by forming of endarterial a plurality of specklees.
Hyperlipemia is most important risk factor for atherosclerosis, and atherosclerosis is the main cause of cardiovascular disease.Hyperlipemia also can be by the type Direct Classification of the lipid raising, i.e. hypercholesterolemia, hypertriglyceridemia or in combined hyperlipidemia, be these two.Lipoprotein (a) (Lipoprotein (a)) level raises also can be classified as a kind of form of hyperlipemia.
People are making great efforts of their low cholesterol level of maintenance now.The typical measure that reduces cholesterol levels is to reduce dietary cholesterol to take in, the using and other treatment (even comprising operation) seldom of some drugs.The present invention provides easily meals mode to reduce cholesterol levels now.
Therefore, compositions of the present invention can be used for reducing total plasma cholesterol level, particularly blood plasma LDL-C level.
Low LDL-C concentration has reduced the risk of cardiovascular disorder.
If the high HDL cholesterol levels of low LDL horizontal integration, this effect is even more remarkable.Can increase by losing weight and/or realizing HDL cholesterol levels by exercise.
If therefore compositions of the present invention is used in heat restricted version and/or be applied to the individuality that regularly carries out exercising with oxygen, be preferred.
The typical cardiovascular disorder that can use compositions prevention of the present invention, improve or treat is optional from atherosclerosis, myocardial infarction, coronary heart disease, apoplexy, peripheral vascular disease or its combination.
In addition or alternatively, compositions of the present invention also can be used for treatment or prevents high blood triglyceride levels and/or relevant obstacle with it.
A major domain of public attention is health of heart.Because the effect of the compositions as herein described of the present invention's proof, compositions of the present invention can be used for promoting health of heart and/or is used for the treatment of, alleviates or prevent health of heart impaired.
In treatment application, cure at least in part or stop the symptom of disease and/or the amount of its complication to use compositions being enough to.The amount that is enough to realize this purpose is defined as to " treatment effective dose ".Effective dose for this object will depend on many factors known to those skilled in the art, for example the seriousness of disease and patient's body weight and overall state.
In prophylactic applications, compositions of the present invention is applied to easy trouble or the risky patient who suffers from specified disease to be enough to reduce at least in part the amount of the risk that disease occurs.This amount is defined as " prevention effective dose ".For example, and accurate amount depends on the factor of many patient-specifics, patient's health status and body weight.
According to dose-effect curve compositions of the present invention, be effective.They can be used with treatment effective dose or prevention effective dose.Technical staff can compatibly determine described dosage.
Yet, common compositions of the present invention can with corresponding to every kg body weight every day at least 0.5g, 1g or 3g Fructus Crataegi and at least the daily dose of 0.6g, 3g or 6g Pueraria lobota use.
For example, compositions of the present invention can comprise at least 0.5g Fructus Crataegi and at least 0.6g Pueraria lobota/kg body weight/day.
Or compositions of the present invention can comprise at least 1g Fructus Crataegi and at least 3g Pueraria lobota/kg body weight/day.
In addition, or compositions of the present invention can comprise at least 3g Fructus Crataegi and at least 6g Pueraria lobota/kg body weight/day.
For avoiding less desirable side effect, such as abnormal flavour, dosage should remain on suitably low level.
For example, the dosage of Fructus Crataegi can be no more than the dosage of 2.5g/kg body weight/day, and the dosage of Pueraria lobota can be no more than 6g/kg body weight/day.
Can provide Fructus Crataegi with any form that is suitable for being applied to human or animal.For example, Fructus Crataegi can be used as fresh fruit, dry fruit, Folium Crataegi or provides as its extract.
Can provide Pueraria lobota with any form that is suitable for being applied to human or animal.For example, Pueraria lobota can be used as Radix Puerariae, Folium Puerariae loatae, Flos puerariae lobatae, dry Pueraria lobota (dried kudzu) or provides as its extract.
Described compositions can be to be suitable for any compositions that human or animal consumes.
So, described compositions is optional from food product, beverage, functional food, nutrition medical science product (nutraceutical), food additive, nutrient formulation product and pet food.
Because the obstacle relevant to hyperlipemia and/or hypercholesterolemia is conventionally with aging appearance, so compositions of the present invention can be applied to adult or old man.
For the object of the invention, if if individual, surpassed half of its country-of-birth basis's average life expectancy, preferably its surpassed its country-of-birth basis's average life expectancy 2/3rds, more preferably its surpassed its country-of-birth basis's average life expectancy 3/4ths, most preferably it surpasses 4/5ths o'clock of its country-of-birth basis's average life expectancy, this individuality should be regarded as " old man ".
For example, compositions of the present invention can be applied to the age 45,50,55,60,65,70,75 or more than 80 years old people.
Because the obstacle relevant to hyperlipemia and/or hypercholesterolemia do not occur over just in the mankind, also occur in animal, so compositions of the present invention can be applied to human or animal, for example companion animals, such as cat or Canis familiaris L..
Guide empty stomach HDL level and heart disease risk being provided based on AHA, NIH and NCEP, causes that lower than the HDL cholesterol levels of 50mg/dL heart disease risk increases lower than the HDL cholesterol levels of 40mg/dL with for women for male.For the HDL cholesterol levels of women 60-50mg/dL with for the HDL cholesterol levels of male 60-40mg/dL, be considered to normal.
Therefore, compositions of the present invention can be applied to and has that 60mg/dL is following, 50mg/dL following or the people of the empty stomach HDL cholesterol levels below 40mg/dL.
AHA, NIH and NCEP also provide a set of guide for empty stomach LDL-cholesterol levels and heart disease risk.
100 to 129mg/dL empty stomach LDL-cholesterol levels is corresponding to approaching best LDL level, corresponding to the more height ratio that develops into the Symptomatic cardiovascular disease event of tool.
130 to 159mg/dL empty stomach LDL-cholesterol levels is corresponding to critical high LDL level, corresponding to the more height ratio that develops into the Symptomatic cardiovascular disease event of tool.
160 to 199mg/dL empty stomach LDL-cholesterol levels is corresponding to high LDL level, corresponding to develop into the Symptomatic cardiovascular disease event of tool high more ratio.
Finally, empty stomach LDL-cholesterol levels more than 200mg/dL is corresponding to very high LDL level, corresponding to the ratio that develops into the increase that the Symptomatic cardiovascular disease event of tool is the highest.
Therefore, compositions of the present invention can be applied to and has that 100mg/dL is above, 130mg/dL above, 160mg/dL is above or the people of empty stomach LDL-C level more than 200mg/dL.
Advantageously, can be before higher fatty acid or high LDL-C meals be about to consume, therewith or just consume compositions of the present invention after consuming.
If meals comprise more than 60%, more than 80% or more than recommending to take in fat mass 100% every day, it will be considered to high-fat.
Similarly, if meals comprise and surpass 60%, surpass 80% or surpass and recommend every day of 100% LDL-C intake, it will be considered to high LDL-C.
So, compositions can be applied from the time range after 1 hour before taking in higher fatty acid and/or high LDL-C meals 1 hour.
It will be understood by those skilled in the art that them can freely combine all features of the present invention as herein described and do not deviate from disclosed scope of the present invention.Particularly, can be by the feature application to described in purposes of the present invention in compositions of the present invention, vice versa.
Other advantage of the present invention and feature are apparent from following embodiment and accompanying drawing.
Fig. 1 demonstration is compared with HFD-placebo, and the combined therapy of Fructus Crataegi and phytosterol reduces cholesterolemia significantly and synergistically at same dose.By single factor ANOVA, measure by Tukey multiple comparisons and independent student t measures analytical data subsequently.Mean value ± SEM, n=8-12, * P<0.05, contrast contrast;
contrast HFD placebo.
Embodiment
The coordinating protection effect to cardiovascular disease of Fructus Crataegi and Radix Puerariae.
Background: the abnormal rising of blood cholesterol levels (hypercholesterolemia) is strongly relevant to cardiovascular disease, because it promotes the atheroma development (atherosclerosis) in tremulous pulse.This lysis causes myocardial infarction (heart attack), apoplexy and peripheral vascular disease.
Blood T-CHOL: treat after 6 weeks, high fat diet (HFD) significantly elevating blood cholesterol reaches 67mg/dL (table 1.1, HFD-placebo contrast contrast).Use the full pulp liquid of Fructus Crataegi or Radix Puerariae water extract treat simultaneously with HFD placebo compare high blood cholesterol levels not significant change (Fig. 1, HFD-K, HFD-H with contrast contrast, * P<0.05; HFD-K, HFD-H and the contrast of HFD-placebo, P>0.05).Although these two independent compositions itself do not show significant protective effect, compare with HFD-placebo, the combined therapy of Radix Puerariae and phytosterol same dose significantly reduce blood cholesterol levels (Fig. 1 .1, HFD-K/H contrast HFD placebo,
).In addition, combined therapy and each separately treatment compare high blood cholesterol levels and show collaborative reducing effect (table 1.1).
Blood T-CHOL (TC) reducing effect of table 1.1. Radix Puerariae (K) water extract and full pulp liquid of Fructus Crataegi (H) in high fat diet (HFD) hamster.
Claims (14)
1. the compositions that comprises Pueraria lobota and Fructus Crataegi, the obstacle that it is used for the treatment of, alleviates or prevention is relevant to hypercholesterolemia.
2. the compositions according to claim 1 for applying, it is for reducing total plasma cholesterol level.
3. the compositions of according to aforementioned claim for applying, it is for reducing blood plasma LDL-C level.
4. the compositions of according to aforementioned claim for applying, the wherein said obstacle relevant to hypercholesterolemia is cardiovascular disorder.
5. the compositions according to claim 4 for applying, wherein said cardiovascular disorder is selected from atherosclerosis, myocardial infarction, apoplexy, peripheral vascular disease or its combination.
6. the compositions of according to aforementioned claim for applying, it is for promoting health of heart and/or being used for the treatment of, alleviating or prevent health of heart impaired.
7. the compositions of according to aforementioned claim for applying, wherein said compositions with corresponding to every kg body weight every day at least 0.5g, 1g or 3g Fructus Crataegi and at least the daily dose of 0.6g, 3g or 6g Pueraria lobota use.
8. the compositions of according to aforementioned claim for applying, wherein Fructus Crataegi is as fresh fruit, dry fruit or be provided as its extract.
9. the compositions of according to aforementioned claim for applying, wherein Ge Zuowei Radix Puerariae, Folium Puerariae loatae, Flos puerariae lobatae, dry Pueraria lobota or be provided as its extract.
10. the compositions according to claim 10 for applying, wherein said extract is water extract.
11. compositionss of according to aforementioned claim for applying, wherein said compositions is selected from food product, beverage, functional food, nutrition medical science product, food additive, nutrient formulation product and pet food.
12. compositionss of according to aforementioned claim for applying, are wherein applied to described compositions adult or old man.
13. compositionss of according to aforementioned claim for applying, are wherein applied to described compositions human or animal, for example companion animals, such as cat or Canis familiaris L..
14. compositionss of according to aforementioned claim for applying, are wherein being applied described compositions from the time range after 1 hour before taking in high fat diet 1 hour.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201380008674.XA CN104105496A (en) | 2012-02-10 | 2013-02-08 | Hawthorn and kudzu and their effect on cardiovascular diseases |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2012/071014 WO2013117006A1 (en) | 2012-02-10 | 2012-02-10 | Hawthorn and kudzu and their effect on cardiovascular diseases |
| CNPCT/CN2012/071014 | 2012-02-10 | ||
| CN201380008674.XA CN104105496A (en) | 2012-02-10 | 2013-02-08 | Hawthorn and kudzu and their effect on cardiovascular diseases |
| PCT/EP2013/052603 WO2013117731A1 (en) | 2012-02-10 | 2013-02-08 | Hawthorn and kudzu and their effect on cardiovascular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104105496A true CN104105496A (en) | 2014-10-15 |
Family
ID=51673073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380008674.XA Pending CN104105496A (en) | 2012-02-10 | 2013-02-08 | Hawthorn and kudzu and their effect on cardiovascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104105496A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106360460A (en) * | 2016-08-27 | 2017-02-01 | 桂林七星粉业有限责任公司 | Processing technology of haw health-care tablets having effect of reducing blood lipid |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1308955A (en) * | 2000-12-20 | 2001-08-22 | 郭兴华 | Natural composition for preventing and treating cardiovascular and cerebrovascular diseases and its application |
| CN1440781A (en) * | 2003-02-26 | 2003-09-10 | 鞍山制药有限公司 | Chinese medicine Xinxuening for treating cardiac and cerebral vascular diseases |
| CN101284058A (en) * | 2008-05-30 | 2008-10-15 | 云南百瑞特生物开发有限公司 | Sobering-up agent and its preparation process |
| CN101797041A (en) * | 2009-02-11 | 2010-08-11 | 张仟 | Food eriosema chinense vinegar fluid with health care special efficacy |
-
2013
- 2013-02-08 CN CN201380008674.XA patent/CN104105496A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1308955A (en) * | 2000-12-20 | 2001-08-22 | 郭兴华 | Natural composition for preventing and treating cardiovascular and cerebrovascular diseases and its application |
| CN1440781A (en) * | 2003-02-26 | 2003-09-10 | 鞍山制药有限公司 | Chinese medicine Xinxuening for treating cardiac and cerebral vascular diseases |
| CN101284058A (en) * | 2008-05-30 | 2008-10-15 | 云南百瑞特生物开发有限公司 | Sobering-up agent and its preparation process |
| CN101797041A (en) * | 2009-02-11 | 2010-08-11 | 张仟 | Food eriosema chinense vinegar fluid with health care special efficacy |
Non-Patent Citations (4)
| Title |
|---|
| 于瑞丽等: "葛根提取物对高尿酸血症模型大鼠尿酸及血脂的影响", 《世界中医药学会联合会亚健康专业委员会换届大会暨中医药与亚健康学术大会》 * |
| 吴中朝主编: "《吴中朝滋补中药150味》", 31 May 2012 * |
| 尤忠一等: "首乌 山楂 葛根等中药合剂的调脂及降ox-LDL作用", 《镇江医学院学报》 * |
| 康旭亮等: "单味中药提取物降血脂的研究进展", 《江西中医学院学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106360460A (en) * | 2016-08-27 | 2017-02-01 | 桂林七星粉业有限责任公司 | Processing technology of haw health-care tablets having effect of reducing blood lipid |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mohamed et al. | Natural anti-obesity agents | |
| CN110583780A (en) | A solid beverage for preventing and reducing hypertension and hyperuricemia | |
| CN104998252B (en) | One kind mends iron blood-enriching oral liquid and preparation method thereof | |
| CN101653249B (en) | Functional food capable of lowering blood sugar and enhancing immunity | |
| CN102246868A (en) | Healthy tea for preventing and controlling arteriosclerosis | |
| CN104105496A (en) | Hawthorn and kudzu and their effect on cardiovascular diseases | |
| CN103735697B (en) | There is Chinese medicine preparation of gout effect and preparation method thereof | |
| CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
| CN102631480A (en) | Toxin-expelling beautifying health-care product | |
| CN102552469A (en) | Health-care product with assistant treatment effect on diabetes, hyperlipidemia and hypertension | |
| CN104379214A (en) | Kudzu and phytosterols for use in the treatment of metabolic disorders | |
| CN104105494A (en) | PHYTOSTEROLS AND KUDZU and effects on CARDIOVASCULAR DISEASES thereof | |
| CN104105497A (en) | Hawthorn and phytosterols and their effect on cardiovascular diseases | |
| CN101554396B (en) | Traditional Chinese medicine for treating diabetes and hyperlipidemia | |
| CN103125701A (en) | Tea formula capable of reducing blood fat viscosity | |
| CN101480434A (en) | Compound recipe for reducing blood fat as well as preparation method and application | |
| KR20160066253A (en) | Composition for preventing or improving metabolic syndrome containing icariside B2 | |
| CN104411319A (en) | Hawthorn and phytosterols and their effect on metabolic disorders | |
| CN102488128B (en) | Food composition having function of assisting in depressing blood-fat and preparation method thereof | |
| CN109662314A (en) | A kind of auxiliary hyperglycemic, compound Hubei Chinese flowering crabapple leaf functional food of reducing blood lipid and preparation method thereof | |
| WO2013117731A1 (en) | Hawthorn and kudzu and their effect on cardiovascular diseases | |
| CN109200183A (en) | A kind of herbal composite and preparation method thereof and product | |
| CN102698185A (en) | Traditional Tibetan medicine for treating hyperlipidemia and preparation method thereof | |
| KR20140046141A (en) | Anti obesity composition | |
| CN102526374B (en) | Hypolipidemic preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20141015 |